NEXGEL Q3 2025 Earnings Call Summary

1Key Financial Results and Metrics

Revenue: $2.9 million, flat year-over-year and slightly higher sequentially.

Gross Profit: $1.24 million, up from $1.16 million year-over-year, with a gross profit margin of 42.4%, an increase from 39.3% in the previous year.

Adjusted EBITDA Loss: Narrowed to $354,000 from $419,000 in Q2 and $500,000 in Q1.

Net Loss: $653,000, improved from a loss of $693,000 in the prior year.

Cash Position: Approximately $938,000 in cash and $920,000 in restricted cash, bolstered by a $1 million non-dilutive financing from Stada.

2Strategic Updates and Business Highlights

Contract Manufacturing: Revenue totaled $907,000, with strong performance from ongoing relationships, particularly with Cintas, which continues to order SilverSeal products.

Partnerships:

Collaboration with iRhythm for their Zio ECG heart monitoring system is expected to generate initial orders this quarter.

Expansion of partnership with Stada, including a soft launch of Gluticin in December and plans for additional product launches in 2026.

Consumer Products: Stable revenue with new product launches anticipated, including lip gloss and eczema solutions. Logistical delays impacted product launches, but these have been resolved.

3Forward Guidance and Outlook

Q4 Expectations: Anticipated record revenues for Q4, with full-year 2025 revenue guidance revised to between $12 million and $12.5 million, driven by a strong holiday season for consumer products.

Profitability: Management aims to narrow adjusted EBITDA losses further, with a potential path to breakeven by year-end.

4Bad News, Challenges, or Points of Concern

Logistical Delays: Unforeseen delays in inventory movement due to customs issues affected product launches, estimated to have cost $100,000 to $200,000 in potential sales.

Dependency on Consumer Products: Future profitability hinges on the performance of new consumer products during the holiday season, which remains uncertain.

AbbVie Partnership Concerns: Uncertainty regarding AbbVie's plans for a recycling device, with conflicting communications causing frustration.

5Notable Q&A Insights

Logistical Delays: Adam Levy clarified that delays were primarily due to customs issues, impacting product launches but not severely affecting existing product sales.

Confidence in Revenue Guidance: Despite flat revenue in recent quarters, management expressed confidence in Q4 growth due to repeat orders and new customer onboarding.

Cash Position: The company maintains a strong cash position, which is expected to improve as inventory is sold in Q4.

Profitability Outlook: Management remains optimistic about achieving a positive EBITDA by year-end, contingent on consumer product performance. Overall, NEXGEL's Q3 2025 results reflect stable revenue with improving margins and a focus on strategic partnerships and new product launches, although challenges related to logistics and dependency on consumer product sales pose risks to achieving profitability.